Aurobindo Pharma rises on getting USFDA`s final approval for Cephalexin Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 1452.90, up by 14.35 points or 1.00% from its previous closing of Rs. 1438.55 on the BSE.
The scrip opened at Rs. 1438.55 and has touched a high and low of Rs. 1459.75 and Rs. 1425.05 respectively. So far 20028 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1592.55 on 13-Sep-2024 and a 52 week low of Rs. 834.90 on 01-Nov-2023.
Last one week high and low of the scrip stood at Rs. 1534.85 and Rs. 1406.85 respectively. The current market cap of the company is Rs. 84384.67 crore.
The promoters holding in the company stood at 51.80%, while Institutions and Non-Institutions held 41.50% and 6.70% respectively.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Cephalexin Tablets USP, 250 mg and 500 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg, of Eli Lilly and Company. Aurobindo Pharma was granted Competitive Generic Therapy (CGT) designation for Cephalexin Tablets USP, 250 mg and 500 mg, and is eligible for 180 days of shared generic drug exclusivity.
The product is expected to be launched in Q3FY25. Cephalexin Tablets USP, 250 mg and 500 mg are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms. Aurobindo Pharma now has a total of 523 ANDA approvals (506 Final approvals and 17 tentative approvals) from USFDA.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
